Treatment of an extracorporeal stream of blood with a dialyzable chemotherapeutic and a fluorescable tracer

• US 4,329,986 A
• Filed: 06/14/1979
• Issued: 05/18/1982
• Est. Priority Date: 06/14/1979
• Status: Expired due to Term

• Current Assignee: Automedix Sciences, Inc. (ICF Corp.)
• Original Assignee: Biomedica Incorporated
• Inventors: Babb, Albert L.
• Primary Examiner(s): Fagelson, Anna P.
• Application Number:
  US06/048,334
• Time in Patent Office: 1,069 Days
• Field of Search: 424/1, 424/1.5, 424/3, 424/7, 424/8, 424/9, 424/101, 424/129, 210/321.2, 210/645, 210/646, 210/647, 210/648, 210/512.1, 210/321.3, 210/927, 250/302, 250/304, 128/214 B, 128/214 R, 128/395, 128/653, 128/654, 128/655, 128/659, 128/760, 23/230 B
• US Class Current: 604/5.04
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients

Abstract

A therapeutic composition suitable for extracorporeal treatment of whole blood comprises a dialyzable chemotherapeutic agent and a dialyzable fluorescable tracer means. The removal rate of the fluorescable tracer compound from treated blood during hemodialysis is a function of the removal rate of unreacted chemotherapeutic agent present. The residual chemotherapeutic agent concentration after hemodialysis is ascertained by measuring the concentration of the fluorescable tracer compound in a dialysate using fluorometric techniques.

Claims

1. A method for treating whole blood with a dialyzable chemotherapeutic agent in an extracorporeal stream of said blood which comprises:

removing whole blood from a patient and forming the whole blood into an extracorporeal stream;

introducing into the extracorporeal stream said chemotherapeutic agent together with a fluorescable tracer means that is dialyzable therefrom at a rate that is a function of the dialysis rate for the chemotherapeutic agent, said fluorescable tracer means being a member of the group consisting of an N-substituted benzamide represented by the formula ##STR2## wherein R is a member of the group consisting of hydrogen and methyl, X is a member of the group consisting of halogen and alkoxy having no more than two carbon atoms, and n is an integer having a value of 0 or 1, and physiologically tolerable alkali metal salts thereof;

dialyzing the extracorporeal stream so as to remove therefrom in a dialysate the chemotherapeutic agent and the tracer means at respective rates that are a function of one another;

irradiating a portion of the obtained dialyzate with fluorescence-exciting electromagnetic radiation;

passing the irradiated portion over a detector means responsive to fluorescence emitted by the tracer means present in said portion and generating an electrical signal having a magnitude indicative of the intensity of emitted fluorescence;

energizing an indicator means with the generated signal;

and returning the blood to the patient.

2. The method in accordance with claim 1 wherein the chemotherapeutic agent is a cyanate and wherein the tracer means is salicylamide.

3. The method in accordance with claim 2 wherein said dialysate is maintained at a pH of about 7.4 and at a temperature of about 40°

C.

4. The method in accordance with claim 1 wherein said dialysate portion is diluted prior to irradiation.

5. The method in accordance with claim 1 wherein the chemotherapeutic agent is sodium cyanate and wherein the tracer means is salicylamide.

6. The method in accordance with claim 1 wherein the chemotherapeutic agent is a cyanate and is introduced into the extracorporeal stream of whole blood in an amount sufficient to provide therein a cyanate concentration of about 0.01 molar to about 0.03 molar, and wherein the tracer means is salicylamide and is introduced into the extracorporeal stream of whole blood in an amount sufficient to provide therein a salicylamide concentration of about 0.14 millimolar to about 0.4 millimolar.

7. The method in accordance with claim 1 wherein the chemotherapeutic agent is sodium cyanate and is introduced into the extracorporeal stream of whole blood in an amount sufficient to provide therein a cyanate concentration of about 0.02 molar, and wherein the tracer means is salicylamide and is introduced into the extracorporeal stream of whole blood in an amount sufficient to provide therein a salicylamide concentration of about 0.27 millimolar.

8. A method for treating whole blood with a dialyzable chemotherapeutic agent in an extracorporeal stream of said blood which comprises:

removing whole blood from a patient and forming the whole blood into an extracorporeal stream;

introducing into the extracorporeal stream said chemotherapeutic agent together with a fluorescable tracer means that is dialyzable therefrom at a rate that is a function of the dialysis rate for the chemotherapeutic agent, said fluorescable tracer means being a member of the group consisting of an N-substituted benzamide represented by the formula ##STR3## wherein R is a member of the group consisting of hydrogen and methyl, X is a member of the group consisting of halogen and alkoxy having no more than two carbon atoms, and n is an integer having a value of 0 or 1, and physiologically tolerable alkali metal salts thereof;

dialyzing the extracorporeal stream so as to remove therefrom the chemotherapeutic agent and the tracer means at respective rates that are a function of one another;

contacting for a predetermined time period at least a portion of the dialyzed extracorporeal stream across a dialysis membrane with an aqueous secondary dialysis solution devoid of said tracer means;

thereafter recovering said aqueous secondary dialysis solution;

irradiating an aliquot of the recovered aqueous secondary dialysis solution with fluorescence exciting electromagnetic radiation;

passing the irradiated aliquot over a detector means responsive to fluorescence emitted by the tracer means present in said aliquot and generating an electrical signal having a magnitude indicative of the intensity of emitted fluorescence;

energizing an indicator means with the generated signal; and

returning the blood to the patient.

9. The method in accordance with claim 8 wherein the tracer means is salicylamide.

10. The method in accordance with claim 8 wherein the chemotherapeutic agent is a cyanate and wherein the tracer means is salicylamide.

11. The method in accordance with claim 8 wherein the chemotherapeutic agent in sodium cyanate and wherein the tracer means is salicylamide.

12. The method in accordance with claim 8 wherein said aqueous secondary dialysis solution is maintained at a pH of about 7.4 and at a temperature of about 40°

C.

13. The method in accordance with claim 8 wherein said predetermined time period is of sufficient duration to substantially equilibrate the concentration of said tracer means in the dialyzed extracorporeal stream and in the secondary dialysis solution.